OneDigital Investment Advisors LLC Sells 9,231 Shares of Kenvue Inc. (NYSE:KVUE)

OneDigital Investment Advisors LLC reduced its position in shares of Kenvue Inc. (NYSE:KVUE) by 33.2% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 18,553 shares of the company’s stock after selling 9,231 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in Kenvue were worth $429,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in KVUE. Huntington National Bank lifted its holdings in Kenvue by 26.5% during the 3rd quarter. Huntington National Bank now owns 4,161 shares of the company’s stock valued at $96,000 after purchasing an additional 871 shares during the last quarter. ING Groep NV boosted its holdings in shares of Kenvue by 23.6% during the 3rd quarter. ING Groep NV now owns 3,576,616 shares of the company’s stock worth $82,727,000 after buying an additional 681,954 shares during the period. Lorne Steinberg Wealth Management Inc. grew its stake in Kenvue by 59.0% in the 2nd quarter. Lorne Steinberg Wealth Management Inc. now owns 154,690 shares of the company’s stock valued at $2,812,000 after buying an additional 57,375 shares during the last quarter. Kennon Green & Company LLC raised its holdings in Kenvue by 140.7% in the 2nd quarter. Kennon Green & Company LLC now owns 159,106 shares of the company’s stock valued at $2,893,000 after acquiring an additional 93,008 shares during the period. Finally, Czech National Bank lifted its position in Kenvue by 20.3% during the second quarter. Czech National Bank now owns 364,886 shares of the company’s stock worth $6,634,000 after acquiring an additional 61,635 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of NYSE:KVUE opened at $23.78 on Thursday. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.13. The stock has a market capitalization of $45.59 billion, a price-to-earnings ratio of 43.07, a price-to-earnings-growth ratio of 2.16 and a beta of 1.36. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company’s 50 day simple moving average is $22.79 and its 200 day simple moving average is $20.78.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The firm had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same quarter last year, the business posted $0.31 EPS. The company’s revenue was down .4% compared to the same quarter last year. As a group, research analysts predict that Kenvue Inc. will post 1.07 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.45%. The ex-dividend date of this dividend is Wednesday, November 13th. Kenvue’s payout ratio is 149.09%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on KVUE shares. Jefferies Financial Group assumed coverage on Kenvue in a research report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 target price on the stock. Bank of America lifted their target price on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. JPMorgan Chase & Co. upped their price target on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Piper Sandler lifted their price objective on shares of Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research note on Monday, September 23rd. Finally, UBS Group raised their target price on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.